EGFR is a transmembrane receptor tyrosine kinase protein, which is expressed in some normal epithelial, mesenchymal, and neurogenic tissue. The overexpression of EGFR has been reported and associated in the pathogenesis of many human malignancies, including NSCLC.&nbsp;&nbsp;
&nbsp;
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Incidence of NSCLC</li>
<li>Total Incident cases of NSCLC patients by Histology</li>
<li>Total Diagnosed cases of NSCLC patients by Stages</li>
<li>Total EGFR-NSCLC cases</li>
<li>EGFR-NSCLC Treated cases&nbsp;</li>
</ul>
&nbsp;
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Epidemiology&nbsp;
<ul>
<li>The incident cases of EGFR mutation in the United States in 2017 were 37,370</li>
<li>The incident population of EGFR-NSCLC in the United States contributed around&nbsp;34%&nbsp;of the total population of EGFR mutated NSCLC in the 7MM in 2017</li>
<li>Among the EU5 countries, Germany had the highest incident population of NSCLC of around&nbsp;29%</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market" target="_blank" rel="noopener noreferrer">Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market</a>
The total market size of EGFR- NSCLC in 7MM&nbsp;in 2017 was&nbsp;USD 1,893 million.&nbsp;&nbsp;
&nbsp;
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Drivers
<ul>
<li>Increasing Use of Biomarker Testing&nbsp;</li>
<li>Increase in the Mutation Specific Trials Activity and Approval</li>
<li>Increasing Incidence of NSCLC</li>
<li>Rich Pipeline and label expansion of approved therapies</li>
</ul>
&nbsp;
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Barriers
<ul>
<li>Cost-Effectiveness of Therapies</li>
<li>Small Patient Populations for Specific Subsets of NSCLC</li>
<li>Generic or Biosimilar Erosion</li>
</ul>
&nbsp;
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Marketed Drugs
The Marketed drugs of the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market are&nbsp;
<ul>
<li>Tagrisso (Osimertinib)</li>
<li>Vizimpro(Dacomitinib)</li>
<li>Tarceva (erlotinib)</li>
<li>Iressa (gefitinib)</li>
<li>Gilotrif (afatinib)</li>
<li>Vizimpro (dacomitinib)</li>
</ul>
And many others.&nbsp;
&nbsp;
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Key Players
The key players in the Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) market are
<ul>
<li>AstraZeneca</li>
<li>Pfizer</li>
<li>Astellas Pharma</li>
<li>Genentech</li>
<li>Boehringer Ingelheim Pharmaceuticals&nbsp;</li>
</ul>
&nbsp;And many others.&nbsp;

EGFR Non-Small Cell Lung Cancer (EGFR+ NSCLC) Market

EGFR Non-Small Cell Lung Cancer (EGFR+ NSCLC) Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.